{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"submitter":["Megyesfalvi Z"],"funding":["Austrian Science Fund FWF","Semmelweis Egyetem","Magyar Tüdőgyógyász Társaság","Innovációs és Technológiai Minisztérium","Magyar Tudományos Akadémia","Nemzeti Kutatási Fejlesztési és Innovációs Hivatal"],"pagination":["674-686"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC9541929"],"repository":["biostudies-literature"],"omics_type":["Unknown"],"volume":["257(5)"],"pubmed_abstract":["The tissue distribution and prognostic relevance of subtype-specific proteins (ASCL1, NEUROD1, POU2F3, YAP1) present an evolving area of research in small-cell lung cancer (SCLC). The expression of subtype-specific transcription factors and P53 and RB1 proteins were measured by immunohistochemistry (IHC) in 386 surgically resected SCLC samples. Correlations between subtype-specific proteins and in vitro efficacy of various therapeutic agents were investigated by proteomics and cell viability assays in 26 human SCLC cell lines. Besides SCLC-A (ASCL1-dominant), SCLC-AN (combined ASCL1/NEUROD1), SCLC-N (NEUROD1-dominant), and SCLC-P (POU2F3-dominant), IHC and cluster analyses identified a quadruple-negative SCLC subtype (SCLC-QN). No unique YAP1-subtype was found. The highest overall survival"],"journal":["The Journal of pathology"],"pubmed_title":["Expression patterns and prognostic relevance of subtype-specific transcription factors in surgically resected small-cell lung cancer: an international multicenter study."],"pmcid":["PMC9541929"],"funding_grant_id":["NAP2‐2017‐1.2.1‐NKP‐00002","UNKP‐19‐4","OTKA 124652","KKP126790","FWF I3522","UNKP‐20‐3","UNKP‐21‐3","FWF I3977","MPA 2020","K129065","OTKA129664","I4677","Bolyai Research Scholarship","TKP2021‐EGA‐33","KH130356","EFOP‐3.6.3‐VEKOP‐16‐2017‐00009","2021‐1.1.6‐JOVŐ"],"pubmed_authors":["Lantos A","Szeitz B","Hirsch FR","Oberndorfer F","Marko-Varga G","Lohinai Z","Renyi-Vamos F","Hoda MA","Laszlo V","Klikovits T","Lang C","Kovacevic M","Bogos K","Rezeli M","Barany N","Ferencz B","Valko Z","Popper H","Kern I","Rivard C","Paku S","Galffy G","Skarda J","Schwendenwein A","Schelch K","Megyesfalvi Z","Dezso K","Brcic L","Fillinger J","Moldvay J","Pipek O","Mittak M","Hoetzenecker K","Dome B"],"additional_accession":[]},"is_claimable":false,"name":"Expression patterns and prognostic relevance of subtype-specific transcription factors in surgically resected small-cell lung cancer: an international multicenter study.","description":"The tissue distribution and prognostic relevance of subtype-specific proteins (ASCL1, NEUROD1, POU2F3, YAP1) present an evolving area of research in small-cell lung cancer (SCLC). The expression of subtype-specific transcription factors and P53 and RB1 proteins were measured by immunohistochemistry (IHC) in 386 surgically resected SCLC samples. Correlations between subtype-specific proteins and in vitro efficacy of various therapeutic agents were investigated by proteomics and cell viability assays in 26 human SCLC cell lines. Besides SCLC-A (ASCL1-dominant), SCLC-AN (combined ASCL1/NEUROD1), SCLC-N (NEUROD1-dominant), and SCLC-P (POU2F3-dominant), IHC and cluster analyses identified a quadruple-negative SCLC subtype (SCLC-QN). No unique YAP1-subtype was found. The highest overall survival","dates":{"release":"2022-01-01T00:00:00Z","publication":"2022 Aug","modification":"2025-04-22T12:05:58.122Z","creation":"2025-04-06T00:14:42.049Z"},"accession":"S-EPMC9541929","cross_references":{"pubmed":["35489038"],"doi":["10.1002/path.5922"]}}